Google announced Wednesday that its quantum computer achieved the first verifiable quantum advantage, running a new algorithm 13,000 times faster than a top supercomputer. The algorithm, called Quantum Echoes, was published in the journal Nature. The results can be replicated on another quantum computer of similar quality, something Google had not demonstrated before. The quantum computer uses a chip called Willow, which was announced in December 2024. Hartmut Neven, head of Google's Quantum AI research lab, called the work a demonstration of the first algorithm with verifiable quantum advantage and a milestone on the software track.

Michel H. Devoret, who won this year's Nobel Prize in Physics and joined Google in 2023, said future quantum computers will run calculations impossible with classical algorithms. Google stopped short of claiming the work would have practical uses on its own. Instead, the company said Quantum Echoes demonstrated a technique that could be applied to other algorithms in drug discovery and materials science.

A second paper published Wednesday on arXiv showed how the method could be applied to nuclear magnetic resonance. The experiment involved a relatively small quantum system that fell short of full practical quantum advantage because it was not able to work faster than a traditional computer. Google exhaustively red-teamed the research, putting some researchers to work trying to disprove its own results.

Prineha Narang, a professor at UCLA, called the advance meaningful. The quantum computer tested two molecules, one with 15 atoms and another with 28 atoms. Results on the quantum computer matched traditional NMR and revealed information not usually available from NMR. Google's research competes against Microsoft, IBM, universities and efforts in China. The Chinese government has committed more than $15.2 billion to quantum research. Previous claims of quantum advantage have been met with skepticism.

The proliferation of difficult-to-treat bacterial diseases represents a growing threat, according to the World Health Organization's (WHO) Global Antibiotic Resistance Surveillance Report. Wired: The report reveals that, between 2018 and 2023, antibiotic resistance increased by more than 40 percent in monitored pathogen-drug combinations, with an average annual increase of 5-15 percent. According to data reported by more than 100 countries to WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS), one in six laboratory-confirmed bacteria in 2023 proved resistant to antibiotic treatment, all related to various common diseases globally.

For the first time, this edition of the report includes prevalence estimates of resistance to 22 antibiotics used to treat urinary tract, gastrointestinal, bloodstream, and gonorrheal conditions. The analysis focused on eight common pathogens: Acinetobacter spp, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae, non-typhoidal Salmonella spp, Shigella spp, Staphylococcus aureus, and Streptococcus pneumoniae. The results show that resistant gram-negative bacteria pose the greatest threat. Of particular note are Escherichia coli and Klebsiella pneumoniae, which are associated with bloodstream infections that can lead to sepsis, organ failure, and death. "More than 40 percent of E. coli and more than 55 percent of K. pneumoniae strains worldwide are now resistant to third-generation cephalosporins, the first-choice treatment for these types of infections," the report warns.

NASA has reopened SpaceX's $4.4 billion moon lander contract to new bidders like Blue Origin and Lockheed Martin after delays in Starship's development threatened the 2027 Artemis 3 mission. Reuters reports: The move paves the way for rivals such as Jeff Bezos' Blue Origin to snatch a high-profile mission to land the first astronauts on the moon in half a century. "I'm in the process of opening that contract up. I think we'll see companies like Blue get involved, and maybe others," the U.S. space agency's acting chief Sean Duffy, who also serves as U.S. Transportation Secretary, told Fox News' "Fox & Friends" program.

Duffy's comments follow months of mounting pressure within NASA to speed up its Artemis lunar program and push SpaceX to make greater progress on its Starship lunar lander, while China progresses toward its own goal of sending humans to the moon by 2030. It represents a major shift in NASA's lunar strategy, starting a new competitive juncture in the program for a crewed moon lander just two years before the scheduled landing date. Blue Origin is widely expected to compete for the mission, while Lockheed Martin has indicated it would convene an industry team to heed NASA's call.

Starship, picked by NASA in 2021 under a contract now worth $4.4 billion, faces a 2027 moon landing deadline that agency advisers estimate could slip years behind schedule, citing competing priorities. Musk sees Starship as crucial to launching larger batches of Starlink satellites to space and eventually ferrying humans to Mars, among other missions. "They do remarkable things, but they're behind schedule," Duffy said of SpaceX's lunar lander work, adding President Donald Trump wants to see the mission take place before his White House term ends in January 2029.